Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Please contact our support expert at support@clementiabiotech.com for data sheet, manuals & quote.

https://www.clementiabiotech.com/products/affinity-biosciences-14-3-3-eta-antibody-affinity-biosciences-df3492-100ul-200ul https://www.clementiabiotech.com/products/affinity-biosciences-14-3-3-eta-antibody-affinity-biosciences-df3492-100ul-200ul https://www.clementiabiotech.com/products/affinity-biosciences-14-3-3-eta-antibody-affinity-biosciences-df3492-100ul-200ul https://www.clementiabiotech.com/products/affinity-biosciences-14-3-3-eta-antibody-affinity-biosciences-df3492-100ul-200ul